PP
AVNR

Paloma Partners’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Paloma Partners’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-30,006
Closed -$358K – 1558
2014
Q3 		$358K Buy
+30,006
New +$205K 0.02% 660
2014
Q2 		– Sell
-48,533
Closed -$178K – 1343
2014
Q1 		$178K Buy
+48,533
New +$185K 0.01% 599

Other funds holding AVNR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Paloma Partners's AVNR Position: Q4 2014 in Review

Paloma Partners sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q4 2014, closing a stake of 30,006 shares — an estimated $358K sold.

Paloma Partners first reported a position in AVNR in Q1 2014 and held it in 2 quarters. The position peaked at $358K in Q3 2014. 166 funds tracked by Wall St. Rank hold AVNR as of Q4 2014.

  • Paloma Partners reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q4 2014 after selling out during the quarter.
  • Paloma Partners sold 30,006 AVANIR PHARMACEUTICALS, INC CL A shares in Q4 2014, an estimated $358K.
  • Paloma Partners first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q1 2014 and held it in 2 quarters.
  • Paloma Partners's AVANIR PHARMACEUTICALS, INC CL A position peaked at $358K in Q3 2014.
  • 166 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q4 2014.

Based on Paloma Partners's 13F filing for Q4 2014, filed 17 Feb 2015.